Sandoz Looks To Build U.S. Injectables Business Through Sabex Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will add Infufer and hydromorphone injectables in the U.S. following $565 mil. transaction. Sabex makes 89 generic molecules for the Canadian market in its FDA-approved facilities.
You may also be interested in...
Novartis Buys Ebewe’s Injectable Cancer Drug Business
The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.
Novartis Buys Ebewe’s Injectable Cancer Drug Business
The €925 million deal provides Novartis’ Sandoz division with a fast-growing generic oncology business and expanded development portfolio.
Novartis' Generics Acquisition Strategy Aims To Add Products, Not Size
Novartis' acquisition strategy for its generics business aims to strengthen Sandoz' negotiating capability with chain pharmacies by adding products to its portfolio rather than simply increasing the business' scale.